Dicerna Pharmaceuticals — Investor Presentation (September 2020)
36 slides from Dicerna Pharmaceuticals's investor presentation, Sep 14, 2020
Slide 1: Corporate Overview: Maximizing the Impact of RNAi on Medicine
Corporate Overview Maximizing the Impact of RNAi on Medicine September 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi
Slide 3: Vision and Strategy
VISION Maximize the impact of RNAi on medicine STRATEGY Develop and commercialize our core high-probability-of-success programs either alone or in collaboration with partners Broadly enable the use of our GalXC technology by collaborating with therapeutic area leaders on non-core opportunities 3
Slide 4: The RNAi Modality Has Come of Age
The RNAi Modality Has Come of Age Many Thousands of Patients Have Been Treated With RNAi Therapeutics Multiple candidates in Approved registration or Dicerna was founded in Products pivotal 2007 to specialize in RNAi development Multiple committed large pharmas Many of the committed pharmas have cho
Slide 5: Dicerna Pipeline of Core and Collaborative Programs
Dicerna Pipeline of Core and Collaborative Programs DISCOVERY/ CLINICAL PROOF-OF- REGISTRATION DICERNA’S CANDIDATE TARGET INDICATION PRECLINICAL RESEARCH CONCEPT TRIALS TRIALS PRODUCT RIGHTS Primary Hyperoxaluria Nedosiran 100% Types 1,2,3 Core RG6346 Hepatitis B Virus U.S. opt-in* Programs (DCR-HBV
Slide 6: We Believe Dicerna Is Creating Best-In-Class Opportunities
We Believe Dicerna Is Creating Best-In-Class Opportunities In Primary Hyperoxaluria Dicerna conducted fundamental disease research to develop the LDHA mechanism to generate the most effective treatment for PH1 and the first treatment for PH2 and PH3 In Hepatitis B Dicerna’s X-sparing approach drives
Slide 7: Platform Expansion to Achieve Effective Extrahepatic Delivery
Platform Expansion to Achieve Effective Extrahepatic Delivery Including Central and Peripheral Nervous Tissues and Other Extrahepatic Tissues GalNAc sugars to bind hepatocyte ASGPR Liver-targeted GalXC is the basis of our current best-in-class core pipeline programs and most of our collaboration pro
Slide 8: Key Achievements and Multiple Upcoming Milestone Targets
Key Achievements and Multiple Upcoming Milestone Targets Nedosiran: Positive first multidose results from PHYOX3 open-label clinical trial – Q1 2020 RG6346: Positive Phase 1 proof-of-concept data from all existing cohorts – Q3 2020 GalXC: Positive data presented for extending GalXC technology
Slide 9: Nedosiran for the Treatment of Primary Hyperoxaluria
Nedosiran for the Treatment of Primary Hyperoxaluria
Slide 10: Primary Hyperoxaluria: Ultra-Rare, Life-Threatening Genetic Disorders
Primary Hyperoxaluria A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications Known Types of Primary Hyperoxaluria The three known types of PH all PH1 PH2 PH3 result in overproduction of oxalate, Genetic mutation Genetic mutation Genetic mutation AGXT GRHPR HOGA1
Slide 11: Positive Interim Results: Nedosiran PHYOX3 Multidose Open-Label Trial
Positive Interim Results: Nedosiran PHYOX3 Multidose Open-Label Trial Mean Value for All Participants (n=11) in Near-Normal Range Starting Day 60 • PHYOX3 ongoing, three-year, multidose, Mean 24-Hour Urinary Oxalate Values open-label extension study (n=11, minimum 5 doses) ‒ Participants are Phase 1
Slide 12: PHYOX3 Interim Analysis: Normalization of Uox
PHYOX3 Interim Analysis: Normalization or Near-Normalization of Uox in 100% of PH1 Patients at One or More Timepoints • 4 of the 11 participants have reached normal Uox at 3 consecutive visits and are eligible for weaning off disease management, including hyperhydration – 1 additional patient who ha
Slide 13: PHYOX3 Interim Safety Data
PHYOX3 Interim Safety Data 301 Study • Favorable risk/benefit profile in this Category n (%) study Total TEAEs 16 (94.1) TEAEs occurring in >=10% of participants in group (n, %) Injection site discomfort 6 (35.3) • AEs mostly related to SC injection Injection site pain 6 (35.3) Injection site erythe
Slide 14: Nedosiran Clinical Trial Program to NDA Filing
Nedosiran Clinical Trial Program to NDA Filing Coordinated Program of Clinical Trials to Support a Broad Label in PH Pivotal Study Package Trial Description/Details Status PH Type Study 201: Pivotal, double-blind, randomized, placebo-controlled Enrolling trial (2:1 randomization) 1,2 n=~36 Monthly f
Slide 15: Nedosiran Target Profile: Only RNAi Candidate for All PH Types
Nedosiran Target Profile: The Only RNAi Drug Candidate in Development for All PH Types High Unmet Medical Need Across All PH Types Can Be Addressed Expected U.S. Prevalence* Education Patient & Diagnostic Caregiver Testing Support Nedosiran Availability Similar numbers for major EU markets Estimated
Slide 16: RG6346 for the Treatment of Hepatitis B Virus Infection
RG6346 for the Treatment of Hepatitis B Virus (HBV) Infection
Slide 17: Hepatitis B: A Severe, Global Unmet Medical Need
Hepatitis B: A Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected • Causes more than 887,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Dicerna is collaborating with Roche to develop RG6346 and potentially other
Slide 18: The Promise of RNAi for the Treatment of Chronic HBV
The Promise of RNAi for the Treatment of Chronic HBV Organization of the HBV Genome Enables Effective RNAi Targeting of Multiple Viral Functions Overlapping mRNAs enable targeting multiple HBV genes with RNAi Dicerna’s RG6346 molecule targets the Conserved S Region Preclinical analysis shows this is
Slide 19: RG6346's X-Sparing Approach Demonstrates Superior HBsAg Reduction
RG6346’s X-Sparing Approach Demonstrates Superior HBsAg Reduction When Targeting Only the Conserved S Region HBsAg Levels in HBV Core Protein HDI-HBV Plasmid Mouse Model Vehicle • With no treatment, Core (cccDNA-dependent) protein is in nucleus and 100 cytoplasm of liver cells Vehicle control 10 S a
Slide 20: RG6346 Phase 1: Three-Part Safety, Tolerability, PK/PD Study
RG6346 Phase 1: Three-Part Safety, Tolerability, PK/PD Study in Healthy Volunteers and Participants With Chronic Hepatitis B Randomized 2:1 active vs placebo, single-ascending- Completed RG6346 dose cohorts: Group A dose study in adult healthy volunteers n=30 0.1, 1.5, 3.0, 6.0, 12.0 mg/kg Randomize
Slide 21: RG6346 Showed Strong, Durable Reduction in HBsAg Levels
RG6346 Showed Strong, Durable Reduction in HBsAg Levels at All Doses Validates Predicted Long Duration of Effect Group C Dosing Cohorts Conditional Follow-Up • Mean maximal HBsAg reduction was 1.88 ⱡ log10 IU/mL (3 mg/kg cohort) ‒ 6 mg/kg cohort ongoing (only 2 of 4 ⱡ participants had reached Day 11
Slide 22: NUC-Naïve Patient With Beneficial Flare
NUC-Naïve Patient With Beneficial Flare As Defined in Clinical Trial Protocol, Suggesting Enhanced Patient Immune Response Two Additional Group B NUC-Naïve Patients Had Similar Beneficial Responses Reductions in All Viral Markers Synthetic and Excretory Liver Function Preserved Coincides with Benefi
Slide 23: RG6346 Appeared Safe and Generally Well Tolerated
In Phase 1 Patients, RG6346 Appeared To Be Safe and Generally Well Tolerated as of the Interim Analysis No Dose Effect on Liver Function Tests Observed in Healthy Volunteers at Dosages ≤12 mg/kg • No serious adverse events (SAEs) associated with RG6346 observed as of June 25, 2020 in Groups B or C ‒
Slide 24: RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response
RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response • Phase 1 proof-of-concept study confirms X-sparing hypothesis and potential for best-in-class activity • Extended duration of effect: 1.5 mg/kg cohort with no reduction in silencing at Day 336 • Beneficial ALT flares consistent wi
Slide 25: DCR-A1AT and ALN-AAT02 for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
DCR-A1AT and ALN-AAT02 for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Slide 26: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Most Disease Is Caused by a Single Missense Allele That Forms Aggregates in Hepatocytes • Alpha-1 antitrypsin (A1AT): predominantly α1-Antitrypsin Deficiency produced in liver and secreted into blood Z mutation Glu342→Lys342 • Pi*ZZ genotype of
Slide 27: Sustained Duration of Activity in Mice and Non-Human Primates
Sustained Duration of Activity Seen in Mice and Non-Human Primates Dosed With DCR-A1AT Sustained, Dose-Dependent Knockdown of A1AT Protein in Both Mice and Monkeys Z-AAT Protein Knockdown in PiZ Mice A1AT Protein Knockdown in Monkeys PBS 3.0 mg/kg 125 3.0 mg/kg 125 10.0 mg/kg 10.0 mg/kg 100 100 SEM
Slide 28: A1AT Clinical Development Program
A1AT Clinical Development Program Seeking a Rapid Path to Approval With the Strongest Candidate • Dicerna and Alnylam are collaborating on their DCR-A1AT and ALN-AAT02 programs • Dicerna is responsible for clinical development through approval, and Alnylam has rights to ex-U.S. commercialization of
Slide 29: GalXC Extrahepatic Platform
oe GalXC® Extrahepatic Platform
Slide 30: Expanding RNAi Delivery to Other Tissues
Expanding RNAi Delivery to Other Tissues Expect Future Pipeline and Collaborations to Include Delivery Beyond Liver Non-Human Primate Gene Silencing Four Weeks After a Single RNAi Dose Central Nervous System Skeletal Muscle Adipose Tissue Single 45 mg i.c.m. Dose Single Subcutaneous Dose Single Subc
Slide 31: Corporate Collaborations
Corporate Collaborations
Slide 32: Successfully Executing on High-Value Collaboration Strategy
Successfully Executing on High-Value Collaboration Strategy Collaborations Have Delivered >$500M in Upfront Payments $175M upfront $75M total annuals $200M upfront $50M equity • 30+ potential $100M upfront • RG6346 and targets for liver- $100M equity multiple potential related CM diseases HBV-relate
Slide 33: Summary
Summary Dicerna ©
Slide 34: Key Achievements and Multiple Upcoming Milestone Targets
Key Achievements and Multiple Upcoming Milestone Targets Nedosiran: Positive first multidose results from PHYOX3 open-label clinical trial – Q1 2020 RG6346: Positive Phase 1 proof-of-concept data from all existing cohorts – Q3 2020 GalXC: Positive data presented for extending GalXC technology
Slide 35: Well Positioned for Near- and Long-Term Success
Well Positioned for Near- and Long-Term Success Driving Growth with Diversified Pipelines and Expanding Technology Platforms • Core Pipeline: Current pipeline yields multiple major milestones over next year+ ‒ Nedosiran: A differentiated therapy for all PH types (PH1, PH2 and PH3) ‒ RG6346: Potentia
Slide 36: Slide 36
Dicerna Pharmaceuticals — Investor Presentation (September 2020) on 6ix